

# Traumatic Brain Injury - Pipeline Review, H1 2020

<https://marketpublishers.com/r/T810F74600DEN.html>

Date: January 2020

Pages: 414

Price: US\$ 2,000.00 (Single User License)

ID: T810F74600DEN

## Abstracts

Traumatic Brain Injury - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Traumatic Brain Injury - Pipeline Review, H1 2020, provides an overview of the Traumatic Brain Injury (Central Nervous System) pipeline landscape.

Traumatic brain injury happens when an external mechanical force causes brain damage. Traumatic brain injury usually results from a violent blow or jolt to the head or body. Symptoms include headache, dizziness, nausea or vomiting, mood changes, fatigue or drowsiness, difficulty sleeping and memory or concentration problems. Risk factor includes age. Certain types of traumatic brain injury increase the risk of developing Alzheimer's disease and coordination problems.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Traumatic Brain Injury - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Traumatic Brain Injury (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Traumatic Brain Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Traumatic Brain Injury and features dormant and discontinued projects. The guide covers therapeutics under Development

by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 7, 8, 2, 93 and 16 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 7 and 2 molecules, respectively.

Traumatic Brain Injury (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Traumatic Brain Injury (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Traumatic Brain Injury (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Traumatic Brain Injury (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Traumatic Brain Injury (Central Nervous System)

therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Traumatic Brain Injury (Central Nervous System)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Traumatic Brain Injury (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Traumatic Brain Injury (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



## Contents

Introduction

Traumatic Brain Injury - Overview

Traumatic Brain Injury - Therapeutics Development

Traumatic Brain Injury - Therapeutics Assessment

Traumatic Brain Injury - Companies Involved in Therapeutics Development

Traumatic Brain Injury - Drug Profiles

Traumatic Brain Injury - Dormant Projects

Traumatic Brain Injury - Discontinued Products

Traumatic Brain Injury - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Traumatic Brain Injury, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Products under Development by Companies, H1 2020  
Products under Development by Universities/Institutes, H1 2020  
Number of Products by Stage and Target, H1 2020  
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020  
Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020  
Number of Products by Stage and Mechanism of Action, H1 2020  
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020  
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020  
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020  
Number of Products by Stage and Route of Administration, H1 2020  
Number of Products by Stage and Molecule Type, H1 2020  
Traumatic Brain Injury - Pipeline by Acelerox LLC, H1 2020  
Traumatic Brain Injury - Pipeline by ALSP Inc, H1 2020  
Traumatic Brain Injury - Pipeline by AlzeCure Pharma AB, H1 2020  
Traumatic Brain Injury - Pipeline by AMAG Pharmaceuticals Inc, H1 2020  
Traumatic Brain Injury - Pipeline by Amarantus Bioscience Holdings Inc, H1 2020  
Traumatic Brain Injury - Pipeline by American CryoStem Corp, H1 2020  
Traumatic Brain Injury - Pipeline by Anagin Inc, H1 2020  
Traumatic Brain Injury - Pipeline by Anida Pharma Inc, H1 2020  
Traumatic Brain Injury - Pipeline by Annovis Bio Inc, H1 2020  
Traumatic Brain Injury - Dormant Projects, H1 2020  
Traumatic Brain Injury - Dormant Projects, H1 2020 (Contd..1), H1 2020  
Traumatic Brain Injury - Dormant Projects, H1 2020 (Contd..2), H1 2020  
Traumatic Brain Injury - Dormant Projects, H1 2020 (Contd..3), H1 2020  
Traumatic Brain Injury - Dormant Projects, H1 2020 (Contd..4), H1 2020  
Traumatic Brain Injury - Discontinued Products, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Traumatic Brain Injury, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Number of Products by Top 10 Targets, H1 2020  
Number of Products by Stage and Top 10 Targets, H1 2020  
Number of Products by Top 10 Mechanism of Actions, H1 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020  
Number of Products by Top 10 Routes of Administration, H1 2020  
Number of Products by Stage and Top 10 Routes of Administration, H1 2020  
Number of Products by Top 10 Molecule Types, H1 2020  
Number of Products by Stage and Top 10 Molecule Types, H1 2020

### COMPANIES MENTIONED

Acelerox LLC  
ALSP Inc  
AlzeCure Pharma AB  
AMAG Pharmaceuticals Inc  
Amarantus Bioscience Holdings Inc  
American CryoStem Corp  
Anagin Inc  
Anida Pharma Inc  
Annovis Bio Inc  
AntiRadical Therapeutics LLC  
Anvyl LLC  
Aptinyx Inc  
Astrocyte Pharmaceuticals Inc  
Athersys Inc  
Avanir Pharmaceuticals Inc  
Bessor Pharma LLC  
Beyond Barriers Therapeutics Inc  
Biogen Inc  
BioIncept LLC  
Bioquark Inc  
Brain-Gen LLC

CalciMedica Inc  
CavoGene LifeSciences  
CellCure  
Cellvation Inc  
CereSpir Inc  
Chimerix Inc  
Chrysalis BioTherapeutics Inc  
Cognosci Inc  
Complement Pharma BV  
Deha Pharmaceutical LLC  
Eagle Pharmaceuticals Inc  
Eisai Co Ltd  
Epigen Biosciences Inc  
Fortuna Fix Inc  
GABA Therapeutics Inc  
GNT Pharma Co Ltd  
Hemarina SA  
Hibernaid Inc  
Hillhurst Biopharmaceuticals Inc  
Hope Biosciences LLC  
Hoverink Biotechnologies Inc  
ImmunoChem Therapeutics LLC  
Impression Healthcare Ltd  
Inflammatory Response Research Inc  
International Stem Cell Corp  
Ischemix Inc  
JT Pharmaceuticals Inc  
Kalytera Therapeutics Inc  
KannaLife Sciences Inc  
LA Cell Inc  
Levolta Pharmaceuticals Inc  
Mapreg SAS  
Mercaptor Discoveries Inc  
MetVital Inc  
NeuExcell Therapeutics Inc  
NeurAegis Inc  
Neuren Pharmaceuticals Ltd  
NeurExo Sciences LLC  
Neurodon LLC



Neuronasal LLC  
NeuroNascent Inc  
NeuroTrauma Sciences LLC  
Neurotrope Bioscience Inc  
NeuroVive Pharmaceutical AB  
New World Laboratories Inc  
NoNO Inc  
NuvOx Pharma LLC  
Nyrada Inc  
OncoSynergy Inc  
Orpheris Inc  
Oxeia Biopharmaceuticals Inc  
Peptron Inc  
Pharmatrophix Inc  
Praetego Inc  
Prevacus Inc  
ProNeurogen Inc  
ProThera Biologics Inc  
Protheragen Inc  
Qrons Inc  
Radikal Therapeutics Inc  
RegeneRx Biopharmaceuticals Inc  
Resolys Bio Inc  
RHNanopharmaceuticals LLC  
Rubicon Biotechnology Inc  
SanBio Inc  
Seneca Biopharma Inc  
Shinkei Therapeutics LLC  
Silver Creek Pharmaceuticals Inc  
Spinogenix Inc  
STATegics Inc  
Stemmedica Cell Technologies Inc  
Swedish Orphan Biovitrum AB  
Tellus Therapeutics Inc  
Tetra Therapeutics  
Thera Neuropharma Inc  
Therapeutic Solutions International Inc  
Therapix Biosciences Ltd  
Theratome Bio Inc

TikoMed AB  
Tiziana Life Sciences Plc  
Tria Bioscience Corp  
vasopharm GmbH  
VG Life Sciences Inc  
Virogenomics BioDevelopment Inc  
Xcelthera INC  
Xonovo Inc  
ZyVersa Therapeutics Inc

## I would like to order

Product name: Traumatic Brain Injury - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/T810F74600DEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T810F74600DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970